The activated STAT3 in the ITE+PD1 group suggests that STAT3 inhibitors shall be explored as an addition to the current combination reported here, specifically in those gliomas with a STAT3 gene signature [42]. This evidence concerns the gene STAT3 and central nervous system cancer.